We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Revised Criteria Proposed for Diagnosis of Alzheimer's Disease

By Biotechdaily staff writers
Posted on 06 Aug 2007
New criteria have been proposed for the diagnosis of Alzheimer's disease (AD). More...


Distinctive and reliable biomarkers are now available for the diagnosis of Alzheimer's disease. These are obtained by cerebrospinal fluid (CSF) analysis, positron emission tomography (PET) neuroimaging, and structural magnetic resonance imaging (MRI).

Recommendations for the new criteria, based on a consensus of an international working group of AD experts, are intended to replace the existing recommendations originally published in 1984 by the U.S. National Institute of Neurological Disorders and Stroke-Alzheimer's Disease and Related Disorders. The team of experts aimed to capture both the earliest stages, before full-blown dementia, as well as the full spectrum of the illness. Validation studies in existing and prospective cohorts are needed to advance these criteria and optimize their sensitivity, specificity, and accuracy.

The new criteria are centered on a clinical core of early and significant episodic memory impairment. The team stipulated that there must also be at least one or more abnormal biomarkers among structural neuroimaging with MRI, molecular neuroimaging with PET, and cerebrospinal fluid analysis of amyloid ß or tau proteins. The timeliness of these criteria is highlighted by the many drugs in development that are directed at changing pathogenesis, particularly the production and clearance of amyloid ß as well as at the hyperphosphorylation state of tau.

Fifteen publications have reported the sensitivity and specificity of the p-tau 231 CSF-based test to be within the range of 85-95 % in various patient populations; one publication showed that the test also has a positive correlation with autopsy confirmation of AD, which is the current gold standard of diagnosis methods.

A report of the group's conclusions was published in the August 2007 issue of The Lancet Neurology. Measurement of the concentration of p-tau, notably p-tau 231, increases the specificity for AD, especially in contrast to fronto-temporal lobar degeneration, the authors wrote.

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
New
Drug Testing Assays
Atellica DT 250 Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: 123RF

UK Project Advances Blood-Based Dementia Testing Toward Routine Clinical Care

Dementia is the leading cause of death in the UK, accounting for almost one in eight deaths, with more than 72,000 people dying from dementia, including Alzheimer’s disease, in 2025. Despite this burden,... Read more

Microbiology

view channel
Image: Overview of a rapid diagnostic workflow for fungal bloodstream infections (Photo courtesy of Professor Hiroki Takahashi and IMO, Chiba University, Japan)

Genomic Workflow Identifies Fungal Pathogens Before Blood Cultures Turn Positive

Fungal bloodstream infections pose a major threat to hospitalized patients. Candida species cause most invasive fungal infections worldwide and are among the leading causes of hospital-acquired bloodstream... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image: TruVerus is designed to deliver a broad menu of routine blood tests from a small blood sample on a single, automated benchtop platform (Photo courtesy of Truvian Health)

Collaboration Advances Automated Benchtop Platform for Routine Blood Testing

Routine blood testing is central to clinical decision-making, but access can vary across laboratory and healthcare settings. Broader use of automated benchtop platforms may help integrate testing more... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.